Mode
Text Size
Log in / Sign up

Influenza A(H3N2)

Part of Influenza

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Influenza A(H3N2)

17 trials tracked for Influenza A(H3N2): 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 134 citations.

17Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 6 Phase 1 2 Other / NA 5
  1. Phase 3 Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza Completed · 134 cited
  2. Phase 3 Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A Completed · 111 cited
  3. Phase 4 Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations Completed
  4. Phase 4 Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents Completed
  5. Phase 2 Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Completed
  6. Phase 2 Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A Completed
Show 11 more trials
  1. Phase 2 A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model Completed
  2. Phase 2 A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Completed
  3. Phase 2 Study Examining PrEP-001 in Healthy Subjects Completed
  4. Phase 2 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A Completed
  5. Phase 1 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Completed
  6. Phase 1 CC-42344 Safety Study in Healthy Participants Completed
  7. N/A Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain Completed
  8. N/A SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings Completed
  9. N/A Collection and Testing of Respiratory Samples Completed
  10. N/A Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus) Completed
  11. N/A MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Influenza

Related studies from across the Influenza family.

High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months
Pediatrics RCT
High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months High-dose flu shots show greater protection for young children in China
This randomized, double-blind study in 3,000 Chinese children aged 6 to 35 months found an investigational high-dose quadrivalent influenza …
A new study in China shows high-dose flu vaccines work as well as or better than standard shots for toddlers, offering stronger protection a…
mRNA-1010 shows superior efficacy against influenza in older adults
Drug Pipeline RCT
mRNA-1010 shows superior efficacy against influenza in older adults New flu shot cuts illness by 27 percent in adults over 50
A phase 3 trial found mRNA-1010 vaccine had 26.6% relative efficacy versus standard comparator in adults 50+.
A new mRNA flu vaccine reduced confirmed flu illness by 27 percent compared with the standard shot in adults 50 and older.
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years
Pediatrics RCT
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years Higher adjuvant content boosts immunity in children without added safety risks
This phase 2, observer-blind, multicenter study evaluated six formulations of MF59-adjuvanted H5N1 vaccine in 420 healthy infants and childr…
A Phase 2 trial in healthy children found that higher adjuvant content improved immune responses to an H5N1 vaccine without increasing side …
Systematic review and meta-analysis finds bacterial co-infection in 17.3% of hospitalized influenza patients
Infectious Disease
Systematic review and meta-analysis finds bacterial co-infection in 17.3% of hospitalized influenza patients Hospital data shows high rates of bacterial co-infection in influenza patients
This systematic review and meta-analysis of 111,889 hospital-attended patients with laboratory-confirmed influenza found a pooled prevalence…
Analysis of over 111,000 patients reveals that bacterial co-infection occurs in 17.3% of hospital cases with confirmed influenza infection.
Coadministration of RSV mRNA vaccine and high-dose flu vaccine noninferior for flu but not for RSV in older adults
Drug Pipeline RCT
Coadministration of RSV mRNA vaccine and high-dose flu vaccine noninferior for flu but not for RSV in older adults New data shows RSV and flu shots work well together
This phase 3 randomized controlled trial in 1900 adults aged 65 and older compared coadministration of mRNA-1345 and quadrivalent influenza …
Older adults can now get their RSV and flu vaccines during one visit without safety risks or extra trips to the clinic for care.
Survey finds physicians show stronger intergroup bias than public on vaccines
Infectious Disease
Survey finds physicians show stronger intergroup bias than public on vaccines Doctors Show Strong Bias Against Vaccine-Hesitant Patients
This review of an online survey in Japan involving 492 physicians and 5,252 members of the general public found that physicians exhibited hi…
Doctors often see themselves as targets of vaccine anger, but new data shows they also hold strong bias against patients who question vaccin…
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions
Drug Pipeline Meta-analysis
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions Ancient Herbs May Help Modern Health
This systematic review synthesizes data on Rhaponticum species, covering 24 documented species worldwide and their applications for conditio…
Imagine walking through a garden filled with wildflowers.
Invasive aspergillosis after COVID-19 linked to higher 14-day mortality than after influenza
Rheumatology Cohort
Invasive aspergillosis after COVID-19 linked to higher 14-day mortality than after influenza Why COVID-19 Makes Lung Fungus Deadlier
This retrospective cohort study of 45 IAPA and 82 CAPA patients found that 14-day mortality risk was 4.92 times higher for CAPA versus IAPA.
Imagine a patient fighting a severe lung infection.
Infection status associated with hypoxemia and death rates varying by virus type in a large US cohort
Geriatrics & Aging Cohort
Infection status associated with hypoxemia and death rates varying by virus type in a large US cohort Triple Virus Infections Rarer Than Feared — Here’s the Real Risk
This cohort study of 835,987 triple-tested patients in the US Veterans Health Administration examined associations between infection status …
It’s winter. Your throat is scratchy. Your chest feels tight.
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens
Infectious Disease Sys. Review
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens New Vaccine Map Helps Pick Best Tools
This narrative review examines virus-like particle (VLP) engineering strategies, including genetic fusion, modular conjugation, and nucleic …
Imagine trying to fix a leaky roof with every tool in the shed.
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection
Genetics & Precision Medicine Cohort
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection New gene signature can spot Ebola infection in blood samples
This observational cohort study analyzed RNA-Seq data from nonhuman primates and human cohorts with Ebola virus infection and comparator inf…
Researchers found a 50-gene signature that reliably separates Ebola from other infections in blood tests, pointing to a future diagnostic to…
Review of intranasal influenza vaccines compared to intramuscular seasonal vaccines
Allergy & Immunology Sys. Review
Review of intranasal influenza vaccines compared to intramuscular seasonal vaccines Your Next Flu Vaccine Might Come From Your Nose
This review evaluates intranasal influenza vaccine platforms, including licensed and emerging replicating and non-replicating types, against…
New flu sprays target the virus at your nose and throat, aiming to stop infection before it enters your body for better protection.